MB
VSTM icon

MPM BioImpact’s Verastem VSTM Stock Holding History

MPM BioImpact’s Portfolio VSTM Stock Details VSTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-270,388
Closed -$2.76M – 42
2022
Q3 		$2.76M Hold
270,388
– – 0.65% 29
2022
Q2 		$3.76M Hold
270,388
– – 1.05% 24
2022
Q1 		$4.58M Sell
270,388
-2,240
-0.8% -$38.6K 1.23% 23
2021
Q4 		$6.71M Buy
272,628
+37,223
+16% +$1.17M 1.22% 22
2021
Q3 		$8.7M Buy
+235,405
New +$8.65M 1.35% 18

Other funds holding VSTM

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's VSTM Position: Q4 2022 in Review

MPM BioImpact sold out of Verastem (VSTM) in Q4 2022, closing a stake of 270,388 shares — an estimated $2.76M sold.

MPM BioImpact first reported a position in VSTM in Q3 2021 and held it in 5 quarters. The position peaked at $8.7M in Q3 2021. 89 funds tracked by Wall St. Rank hold VSTM as of Q4 2022.

  • MPM BioImpact reported no remaining Verastem position as of Q4 2022 after selling out during the quarter.
  • MPM BioImpact sold 270,388 Verastem shares in Q4 2022, an estimated $2.76M.
  • MPM BioImpact first reported a position in Verastem in Q3 2021 and held it in 5 quarters.
  • MPM BioImpact's Verastem position peaked at $8.7M in Q3 2021.
  • 89 funds tracked by Wall St. Rank held Verastem as of Q4 2022.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.